BioSpectrum Asia
July 2025
Medical Advances Soar With APAC'S CLINICAL TRIAL GROWTH

It's a truth universally acknowledged that Asia-Pacific is a hotbed for clinical trials, with multiple reports confirming that it is the only region in the world to have seen a consistent surge in clinical trial activity. The Asia Pacific clinical trials market generated a revenue of $15.91 billion in 2023 and is expected to reach a projected revenue of $25.99 billion by 2030 at a compound annual growth rate of 7.3 per cent, according to the Grand View Research report. Between 2020 and 2025, China, India, Australia, Japan, South Korea, and Singapore emerged as key pillars of Asia-Pacific’s growing clinical trial ecosystem. Together, these six countries accounted for nearly 40,000 trials (39,843 in total). We take a close look at each country’s clinical trial landscape, examining who is leading in which phases, how domestic players compare to multinational sponsors, and which therapeutic areas are seeing the most activity. We also explore the challenges of running trials across such a diverse region. Let’s dive in.

BioSpectrum Asia
June 2025
APAC'S ALLIANCE-DRIVEN BIOTECH BOOM

Partnerships are a cornerstone of the biotech innovation process. COVID-19 acted as a catalyst, accelerating collaboration across the sector and prompting partnerships between established players for the first time. Since then, biotech alliances have become more diverse, frequent, and strategically important, especially in the Asia-Pacific (APAC) region. Biotech partnerships of APAC differ in a variety of ways from most global collaborations, primarily due to the unique geopolitical and socio-economic landscape of the region. The region has innovation hubs like Japan and South Korea as well as large, high-growth markets such as China and India. As China rapidly scales its biopharma capabilities, it is becoming both a key market and an innovator. This transformation has redefined regional deal-making, shifting the focus from technology transfer to co-development, shared commercialisation, and strategic alignment. APAC biotech deals are no longer early-stage R&D plays, they are beginning to span the full lifecycle, from bench to bedside, including commercialisation milestones. Let’s explore further the APAC's wave of regional biotech partnerships during the first five months of this calendar year ie. from January to May 2025.

BioSpectrum Asia
May 2025
APAC VACCINE POWERHOUSES Flex Capacity & Quality Muscle

Asia is the epicentre of global vaccine manufacturing, with India and China together supplying over a billion doses annually. Now, emerging players like South Korea, Singapore, and Australia are stepping up, investing in next-gen platforms and expanding capacity to meet global demand. Let’s map the manufacturing footprint of Asia’s leading vaccine manufacturers, tracking their current capacity, expansion plans, and the strategic shifts that are transforming the region into a global vaccine production hub.

BioSpectrum Asia
April 2025
CDMOs CLEAN UP ACT: Environmental Responsibility

Contract development and manufacturing organisations (CDMOs) are facing increasing pressure to reduce their environmental footprint. The Clean Up Act, which came into effect in 2024, requires companies to report their environmental impact and take steps to reduce it. This has led to a shift in the industry, with CDMOs investing in green technologies and processes to reduce their environmental impact.

BioSpectrum Asia
March 2025
Mitigating PATENT CLIFF Fallout

Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.

BioSpectrum Asia
February 2025
APAC takes Centre stage in AI-Driven Drug Discovery

The Asia-Pacific (APAC) region is rapidly emerging as a leader in AI-driven drug discovery, fuelled by robust research ecosystems and strong industry collaboration. Substantial investments, cutting-edge technologies, and strategic partnerships are optimising drug development efficiency. As Artificial Intelligence (AI) has become more embedded into many facets of everyday life, it has become an indispensable part of the drug discovery landscape. 2024 was the year of reckoning when AI in drug discovery received the highest validation—three researchers who leveraged the neural network AI programme AlphaFold to predict protein structures won the Nobel Prize in Chemistry. The industry is pushing ahead, using tech to make the business of drug development faster, safer, and more economical. Morgan Stanley estimates that AI's use in drug development could lead to 50 more successful treatments over a decade, potentially creating a $50 billion market. Let’s explore the region's efforts in accelerating drug development through AI.

BioSpectrum Asia
January 2025
BioSpectrum Asia Excellence Awards 2024:Honouring Innovators in Asia's Thriving Life Sciences Sector

Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024. These awards are an extension to observe and highlight the winners in the long battle against the world's emerging health problems and to find solutions. BioSpectrum Asia has taken up the enviable role of identifying and highlighting tomorrow's winners. These awards, we hope, will encourage today's entrepreneurs to better their past successes, while honouring yesterday's stalwarts who played a key role in their success.

Explore the Earlier Issues

Explore the Last Year Issues